Ibrahim A. Aljuffali

2.8k total citations
82 papers, 2.2k citations indexed

About

Ibrahim A. Aljuffali is a scholar working on Pharmaceutical Science, Dermatology and Molecular Biology. According to data from OpenAlex, Ibrahim A. Aljuffali has authored 82 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pharmaceutical Science, 25 papers in Dermatology and 16 papers in Molecular Biology. Recurrent topics in Ibrahim A. Aljuffali's work include Advancements in Transdermal Drug Delivery (28 papers), Dermatology and Skin Diseases (12 papers) and Skin Protection and Aging (9 papers). Ibrahim A. Aljuffali is often cited by papers focused on Advancements in Transdermal Drug Delivery (28 papers), Dermatology and Skin Diseases (12 papers) and Skin Protection and Aging (9 papers). Ibrahim A. Aljuffali collaborates with scholars based in Saudi Arabia, Taiwan and United States. Ibrahim A. Aljuffali's co-authors include Jia‐You Fang, Chih-Hung Lin, Shih-Chun Yang, Calvin T. Sung, Chia-Lang Fang, Chi‐Feng Hung, Chwan‐Fwu Lin, Tai‐Long Pan, Chi-Ting Huang and Pei‐Wen Wang and has published in prestigious journals such as Journal of Controlled Release, International Journal of Pharmaceutics and Pharmaceutical Research.

In The Last Decade

Ibrahim A. Aljuffali

80 papers receiving 2.2k citations

Peers

Countries citing papers authored by Ibrahim A. Aljuffali

Since Specialization

Citations

This map shows the geographic impact of Ibrahim A. Aljuffali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ibrahim A. Aljuffali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ibrahim A. Aljuffali more than expected).

Fields of papers citing papers by Ibrahim A. Aljuffali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ibrahim A. Aljuffali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ibrahim A. Aljuffali. The network helps show where Ibrahim A. Aljuffali may publish in the future.

Co-authorship network of co-authors of Ibrahim A. Aljuffali

This figure shows the co-authorship network connecting the top 25 collaborators of Ibrahim A. Aljuffali. A scholar is included among the top collaborators of Ibrahim A. Aljuffali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ibrahim A. Aljuffali. Ibrahim A. Aljuffali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	RNA-Based Antipsoriatic Gene Therapy: An Updated Review Focusing on Evidence from Animal Models 2024 ·Drug Design Development and Therapy ·Zih‐Chan Lin, Chi‐Feng Hung, Ibrahim A. Aljuffali, Ming‐Hsien Lin, Jia‐You Fang	6
2	Development of Gefitinib-Loaded Solid Lipid Nanoparticles for the Treatment of Breast Cancer: Physicochemical Evaluation, Stability, and Anticancer Activity in Breast Cancer (MCF-7) Cells 2023 ·Pharmaceuticals ·Ibrahim A. Aljuffali, Md. Khalid Anwer, Mohammed Muqtader Ahmed, Ahmed Alalaiwe, Mohammed F. Aldawsari, Farhat Fatima, (unknown)	4
3	Combining the dual antibacterial and regenerative activities of platelet-rich plasma with β-lactams to mitigate MRSA-infected skin wounds 2023 ·Biomedicine & Pharmacotherapy ·Shih-Chun Yang, Chwan‐Fwu Lin, (unknown), Ibrahim A. Aljuffali, (unknown), Jia‐You Fang	7
4	National medicines policy development, Saudi Arabia 2022 ·Bulletin of the World Health Organization ·(unknown), (unknown), (unknown), Ibrahim A. Aljuffali, Nahar Alazemi, Taghred Alghaith, (unknown), (unknown), Andreas Seiter, Christopher H. Herbst, Elizabeth Pisani	4
5	Pharmaceutical companies’ views on a health technology assessment (HTA) entity in Saudi Arabia 2020 ·Saudi Pharmaceutical Journal ·Hussain Abdulrahman Al‐Omar, (unknown), Ibrahim A. Aljuffali	11
6	Exploring the structure-permeation relationship of topical tricyclic antidepressants used for skin analgesia 2017 ·International Journal of Pharmaceutics ·Kuo‐Sheng Liu, Tse‐Hung Huang, Ibrahim A. Aljuffali, (unknown), Jhi‐Joung Wang, Jia‐You Fang	6
7	Intravenous anti-MRSA phosphatiosomes mediate enhanced affinity to pulmonary surfactants for effective treatment of infectious pneumonia 2017 ·Nanomedicine Nanotechnology Biology and Medicine ·Ching‐Yun Hsu, Calvin T. Sung, Ibrahim A. Aljuffali, Chun‐Han Chen, (unknown), Jia‐You Fang	24
8	Derivatization of honokiol by integrated acetylation and methylation for improved cutaneous delivery and anti-inflammatory potency 2017 ·European Journal of Pharmaceutical Sciences ·Jia‐You Fang, Tse‐Hung Huang, Chi‐Feng Hung, Yu‐Ling Huang, Ibrahim A. Aljuffali, (unknown), Chwan‐Fwu Lin	11
9	Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers 2016 ·Current Pharmaceutical Design ·Ibrahim A. Aljuffali, Chia-Lang Fang, Chun‐Han Chen, Jia-You Fang	35
10	The roles of the virulence factor IpaB in Shigella spp. in the escape from immune cells and invasion of epithelial cells 2015 ·Microbiological Research ·Shih-Chun Yang, Chi‐Feng Hung, Ibrahim A. Aljuffali, Jia‐You Fang	34
11	The Saudi Arabia Food and Drug Authority: An Evaluation of the Registration Process and Good Review Practices in Saudi Arabia in Comparison with Australia, Canada and Singapore 2015 ·Pharmaceutical Medicine ·(unknown), Ibrahim A. Aljuffali, (unknown), Stuart Walker	17
12	Cationic liposomes evoke proinflammatory mediator release and neutrophil extracellular traps (NETs) toward human neutrophils 2015 ·Colloids and Surfaces B Biointerfaces ·Tsong‐Long Hwang, Ching‐Yun Hsu, Ibrahim A. Aljuffali, Chun-Han Chen, (unknown), Jia‐You Fang	28
13	Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury: An animal study 2015 ·Journal of Controlled Release ·Chia-Lang Fang, (unknown), Ibrahim A. Aljuffali, Calvin T. Sung, (unknown), Jia-You Fang	31
14	Cutaneous Delivery of Natural Antioxidants: The Enhancement Approaches 2015 ·Current Pharmaceutical Design ·Ibrahim A. Aljuffali, Ching‐Yun Hsu, Yin‐Ku Lin, Jia‐You Fang	12
15	Development and validation of stability-indicating high performance liquid chromatography method to analyze gatifloxacin in bulk drug and pharmaceutical preparations 2014 ·Saudi Pharmaceutical Journal ·Ibrahim A. Aljuffali, Mohd Abul Kalam, Yasmin Sultana, Ahamad Imran, Aws Alshamsan	12
16	Impact of Ester Promoieties on Transdermal Delivery of Ketorolac 2014 ·Journal of Pharmaceutical Sciences ·Kuo‐Sheng Liu, Pei‐Wen Hsieh, Ibrahim A. Aljuffali, Yin‐Ku Lin, (unknown), Jhi‐Joung Wang, Jia‐You Fang	8
17	Coumarin derivatives, but not coumarin itself, cause skin irritation via topical delivery 2014 ·Toxicology Letters ·Tai‐Long Pan, Pei‐Wen Wang, Ibrahim A. Aljuffali, Yann‐Lii Leu, (unknown), Jia‐You Fang	9
18	Co-Drug Strategy for Promoting Skin Targeting and Minimizing the Transdermal Diffusion of Hydroquinone and Tranexamic Acid 2013 ·Current Medicinal Chemistry ·Pei‐Wen Hsieh, Weiyu Chen, Ibrahim A. Aljuffali, (unknown), Jia‐You Fang	25
19	Squarticles as a Lipid Nanocarrier for Delivering Diphencyprone and Minoxidil to Hair Follicles and Human Dermal Papilla Cells 2013 ·The AAPS Journal ·Ibrahim A. Aljuffali, Calvin T. Sung, Fengming Shen, Chi-Ting Huang, Jia‐You Fang	66
20	Part I: Development and optimization of solid‐lipid nanoparticles using Box–Behnken statistical design for ocular delivery of gatifloxacin 2012 ·Journal of Biomedical Materials Research Part A ·Mohd Abul Kalam, Yasmin Sultana, Asgar Ali, Mohd. Aqil, Anil K. Mishra, Ibrahim A. Aljuffali, Aws Alshamsan	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact